#f9f9f9

Allison Churchfield

Carlos Alban

Andy Kozar

Yan Gao

Richard A. Gonzalez

Dalia Mahmoud

Michael Paas

Pieter Drost Pharm

Whitney Morris

#1292ef

AbbVie

#87c5f2

Market Access Immunology

Market Access & Pricing 

Oncology Global Commercial Development

Marketing for Hematology - Venclexta in AML

Rafael Labrador

Marketing - Solid Tumors

Oncology Business Unit

Jason Rupnick

Corporate Business Development and Acquisitions

Companion Diagnostics Commercialization Lead for Oncology

Oncology Global Marketing

Tom Spalding

Medical Science Liaison(Immunology)

Jennifer Feeley

Annette Montandon

Nolan Panneck

Medical Science Liaison(Oncology)

Field Access & Reimbursement Immunology

Tanya Schooley

Market Access Oncology

Lori Bollom

Field Access & Reimbursement

Devi Prasad Pulla

Field Access & Reimbursement Oncology

Jen Doherty

HEOR Immunology

Medical Science Liaison

HEOR Oncology

Global Commercial Operations

William Vollmer

Meg Amplement

Kun Lee

Michael Scott

Nelson Lin

Klaus Damm

Jay Stamatis

Rahul Jerath

Rachel Zimet Strick

Other Market Access

HEOR

Market Access

Search & Evaluation

Niels Emmerich

Search & Evaluation Oncology

Vivek Abraham

Tatyana Kapustyan

Market Access & Pricing Oncology

Graeme Griffin

Anthony Brazda

Christa Gott

Claudina Stevenson

Wes Matthias

National Account

Healthcare Solutions, Oncology

Marketing

Managed Healthcare Marketing, Oncology and MS

New Product Planning & Business Insight

Other Marketing

Tania Molinaro

Commercial operations

Oncology Marketing US

Vandana Rajakumar

Mike Hale

Jason Santiago

Mundo Vega

Michelle Van Der Woert

Matt Bennett

Denise Pettiecord

Alexandre Volkoff

Abed Haddad

Business Development & Acquisitions Oncology

Mike Halpin

Oncology Licensing and Acquisitions

Commercial Insights - U.S. Oncology

Kathleen (kathie) Miller

Commercial Analytics for Oncology

Oncology - Global Market Analytics & Business Intelligence

Melanie Amidei

National Sales Oncology 

Brand Marketing, Oncology

Oncology Franchise Marketing

AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. AbbVie combines the focus and passion of a leading-edge biotech with the ... 

AbbVie’s patient assistance
Our approach to innovation builds on strong science combined with the drive to find solutions where the need is the greatest
Focus areas
Careers
26 nonprofits
88%
Patients
If we bring a new medicine to market, it can help patients worldwide, as opposed to the 20 or so patients we might see in clinic in one day. That's what drives me. It's the greater impact we can have by working here at AbbVie.
Kyle Holen, M.D., Vice President, General Medicine and Infectious Diseases
AbbVie combines advanced science, expertise and passion to solve the world’s most serious health issues and have a remarkable impact on people’s lives
AbbVie was named to the DJSI World Index for the seventh year in a row for our responsible economic, environmental and social performance
DiversityInc Top 50 Companies for Philanthropy
AbbVie ranked No. 5 on DiversityInc’s list for 2020. DiversityInc also recognized AbbVie as one of the Top 50 Companies for Diversity this year
Seven years on The Civic 50
For the seventh year in a row, AbbVie was named on The Civic 50, a listing of the most community-minded companies in the United States
Copyright © 2021 AbbVie Inc. North Chicago, Illinois, U.S.A.
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.
×
You are about to leave the AbbVie website
The product-specific site Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals that are not approved in other countries or region. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence. The Internet site that you have requested may not be optimized to your screen size. Do you wish to continue to this product-specific site?
You are about to leave for a 3rd party website
The link below will take you out of the AbbVie family of websites. Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie. The Internet site that you have requested may not be optimized to your screen size. Do you wish to leave this site?
The online application portal is for HUMIRA, RINVOQ, or SKYRIZI only. For all other medicines, please visit the Find My Medicine page.
Disclaimer Notice - Important
Recommended Offer for Allergan plc (“Allergan”) by AbbVie Inc. (“AbbVie”) (the “Acquisition”) by means of a scheme of arrangement under Irish law (the “Scheme”). You are attempting to enter the section of this website that is designated for the publication of documents and information in connection with the offer by AbbVie for Allergan announced on June 25, 2019 (the “Offer”). ACCESS TO THIS SECTION OF THE WEBSITE MAY BE RESTRICTED UNDER SECURITIES LAWS IN CERTAIN JURISDICTIONS. THIS NOTICE REQUIRES YOU TO CONFIRM CERTAIN MATTERS (INCLUDING THAT YOU ARE NOT RESIDENT IN SUCH A JURISDICTION), BEFORE YOU MAY OBTAIN ACCESS TO THE INFORMATION. THE INFORMATION IS NOT DIRECTED AT, AND IS NOT INTENDED TO BE ACCESSIBLE BY, PERSONS RESIDENT IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. IF YOU ARE NOT PERMITTED TO VIEW THE INFORMATION, OR VIEWING THE INFORMATION WOULD RESULT IN A BREACH OF THE ABOVE, OR YOU ARE IN ANY DOUBT AS TO WHETHER YOU ARE PERMITTED TO VIEW THE INFORMATION, PLEASE EXIT THIS WEBPAGE. THIS SECTION OF THE WEBSITE CONTAINS ANNOUNCEMENTS, DOCUMENTS AND INFORMATION (TOGETHER THE "INFORMATION") RELATING TO THE OFFER IN COMPLIANCE WITH THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES 2013 (THE "IRISH TAKEOVER RULES"). THE INFORMATION IS BEING MADE AVAILABLE IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY, AND ITS AVAILABILITY IS SUBJECT TO THE TERMS AND CONDITIONS SET OUT BELOW. THE INFORMATION IS NOT INTENDED TO, AND DOES NOT, CONSTITUTE OR FORM ANY PART OF AN OFFER TO SELL OR OTHERWISE DISPOSE OF OR AN INVITATION OR THE SOLICITATION OF AN OFFER TO PURCHASE OR OTHERWISE ACQUIRE ANY SECURITIES, OR THE SOLICITATION OF A VOTE OR APPROVAL PURSUANT TO THE INFORMATION OR OTHERWISE. ANY PERSON SEEKING ACCESS TO THIS SECTION OF ABBVIE’S WEBSITE REPRESENTS AND WARRANTS TO ABBVIE THAT THEY ARE DOING SO FOR INFORMATION PURPOSES ONLY. BASIS OF ACCESS TO INFORMATION Please read this notice carefully before clicking "I agree" or "I disagree" below. This notice applies to all persons who view this section of the website and, depending on where you live, it may affect your rights. This notice may be amended or updated by AbbVie from time to time and it should be read carefully in full each time you wish to view the website. In addition, the content of the website, and its accessibility by certain persons, may be amended at any time in whole or in part at the sole discretion of AbbVie. The Information speaks only at the date of the relevant document or announcement and AbbVie has, and accepts, no responsibility or duty to update any Information (other than to the extent such duty arises as a matter of law or regulation).


We’re dedicated to finding new ways to bring relief to our many patients living with debilitating, immune-mediated inflammatory conditions.